A comparison of 67Cu- and 131I-labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer
Alan Smith
Division of Radiopharmacy, Paul Scherrer Institute, Würenlingen
Search for more papers by this authorUwe Zangemeister-Wittke
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorRobert Waibel
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorThomas Schenker
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorCorresponding Author
P. August Schubiger
Division of Radiopharmacy, Paul Scherrer Institute, Würenlingen
PSI, CH-5232 Villigen/PSI, SwitzerlandSearch for more papers by this authorRolf A. Stahel
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorAlan Smith
Division of Radiopharmacy, Paul Scherrer Institute, Würenlingen
Search for more papers by this authorUwe Zangemeister-Wittke
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorRobert Waibel
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorThomas Schenker
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorCorresponding Author
P. August Schubiger
Division of Radiopharmacy, Paul Scherrer Institute, Würenlingen
PSI, CH-5232 Villigen/PSI, SwitzerlandSearch for more papers by this authorRolf A. Stahel
Department of Oncology, University Hospital, Zurich, Switzerland
Search for more papers by this authorAbstract
The intact anti-SCLC monoclonal antibody (MAb) SEN7 and its F(ab')2 were labelled with the β-emitting isotope 67Cu. Both materials retained their biological activity in vitro as determined by the Lindmo assay. In a direct comparison of in vivo distribution in a xenograph model, 131I- and 67Cu-labelled intact SEN7 showed similar absolute tumour accumulation. Blood levels were markedly lower in the case of the 67Cu-labelled antibody, resulting in improved tumour:blood ratios which reached a maximum of 13:1 compared with only 4.5:1 for 131I-SEN7. In the case of the 67Cu-labelled F(ab')2, very high accumulation of the nuclide was observed in the kidney. Levels of radio copper in liver and spleen were also found to be significantly raised when compared with radio iodine. SWA20, a MAb which had previously failed to show any selective in vivo accumulation in tumour xenografts when labelled with radio iodine showed higher and more stable tumour accumulation when labelled with 67Cu.
References
- Anderson, C. J., Connett, J. M., Schwarz, S. W., Rocque, P. A., Guo, L. W., Philpott, G. W., Zinn, K. R., Wears, C. F. and Welch, M. S., Copper-64-labeled antibodies for PET imaging. J. nucl. Med., 33, 1685–1691 (1992).
- Beaumier, P. L., Vankatesan, P., Vanderheyden, J. L., Burgua, W. D., Kunz, L. L., Fritzberg, A. R., Abrams, P. G. and Morgan, A. C., 186Re radioimmunotherapy of small-cell-lung-carcinoma xenografts in nude mice. Cancer Res., 51, 676–681 (1991).
- Carney, D. N., Clinical implications of the biology of small-cell lung cancer. Europ. J. Resp. Dis., 70, Suppl. 149-, 5–9 (1987).
- De Leij, L., Berendsen, H. and The, H., Small-cell lung cancer. Europ. J. Resp. Dis., 70, Suppl. 149, 1–4 (1987).
- DeNardo, G. L., DeNardo, S. J., O'Grady, L. F., Mills, S. L., Lewis, J. P. and Macey, D. J., Radiation treatment of B-cell malignancies with immunoconjugates. In: J. M. Vaeth (ed.). Frontiers of radiation therapy and oncology: the present and future role of monoclonal antibodies in the management of cancer, Vol. 24, pp. 194–201, Karger, Basel (1990).
- Dykes, P. W., Bradwell, A. R., Chaoman, C. E. and Vaughan, A. T. M., Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat. Rev., 14, 87–106 (1987).
- Halpern, S. E., Haindi, W., Beauregard, R. N., Hagan, P., Clutter, M., Amox, D., Merchant, B., Unger, M., Mongovi, C., Bartholomew, R., Jue, R., Crlo, D. and Dillman, R., Scintigraphy with In-III-labeled monoclonal antibodies: kinetics, biodistribution, and tumor detection. Radiology, 168, 529–536 (1988).
- Humm, J. L., Dosimetric aspects of radiolabeled antibodies for tumor therapy. J. nucl. Med., 27, 1490–1497 (1986).
- Milenic, D. E., Esteban, J. M. and Colcher, D., Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J. immunol. Methods, 120, 71–83 (1989).
- Morphy, J. R., Parker, D., Kataky, R., Eaton, M. A. W., Millican, A. T., Alexander, R., Harrison, A. and Walker, C., Towards tumour targeting with copper-radiolabelled macrocycle-antibody conjugates: synthesis, antibody linkage, and complexation behaviour. J. chem. Soc., Perkin Trans., 2, 792–794 (1990).
- Press, O. W., DeSantes, K., Anderson, S. K. and Geissler, F., Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosmmotropic amines and carboxylic ionophores. Cancer Res., 50, 1243–1250 (1990).
- Scheinberg, D. A., Lovett, D., Divgi, C. R., Graham, M. C., Berman, E., Pentlow, K., Feirt, N., Finn, R. D., Clarkson, B. D., Gee, T. S., Larson, S. M., Oettgen, H. F. and Ole, L. J., A phase-I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone-marrow targeting and internalization of radionuclide. J. clin. Oncology, 9, 478–490 (1991).
- Sgouros, G., Bone-marrow dosimetry for radioimmunotherapy: theo-retical considerations. J. nucl. Med., 34, 689–694 (1993).
- Smith, A., Alberto, R., Blaeuenstein, P., Novak-Hofer, I., Maecke, H. and Schubiger, P. A., Pre-clinical evaluation of 67Cu-labeled intact and fragmented anti-colon-carcinoma monoclonal antibody Mab35. Cancer Res., 5727–5733 (1993).
- Smith, A., Waibel, R. and Stahel, R. A., Selective immunotherapy of small-cell-cancer xenografts using 131O-labelled SWA11 antibody. Brit. J. Cancer, 64, 263–266 (1991).
- Smith, A., Waibel, R., Westera, G., Martin, A., Zimmerman, A. T. and Stahel, R. A., Immunolocalisation and imaging of small-cell-cancer xenografts by the IgG2a monoclonal antibody SWA11. Brit. J Cancer, 59, 174–178 (1989).
- Smith-Jones, P. M., Fridrich, R., Kaden, T. A., Novak-Hofer, I., Siebold, K., Tschudin, D. and Maecke, H. R., Antibody labeling with copper-67 using the bifunctional macrocycle-4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid. Bioconjugate Chem., 2, 415–421 (1991).
- Stahel, R. A., Speak, J. A. and Bernai, S. D., Murine monoclonal antibody LAM2 defines cell-membrane determinant with preferential expression on human small-cell carcinoma and squamous-cell carcinoma. Int. J. cancer, 35, 11–17 (1985).
- Studer, M. and Kaden, T. A., One-step synthesis of mono-N-substituted azamacrocycles with a carboxylic group in the side chain, and their complexes with Cu2+ and Ni2+. Helv. chim. Acta, 69, 2081–2086 (1986).
- Trucco, M. and de Petris, S., Determination of equilibrium-binding parameters of monoclonal antibodies specific for cell-surface antigens. Immunol. Methods, 1–26 (1981).
- Waibel, R., Mannhart, M., O'Hara, C. J., Brockelhurst, C., Zangemeister-Wittke, U., Schenker, T., Lehman, H. P., Weber, E. and Stahel, R. A., Monoclonal antibody SEN7 recognizes a new epitope on the neural-cell adhesion molecule present on small-cell lung cancer but not on lymphocytes. Cancer Res., 53, 2840–2845 (1993).
- Waibel, R., O'Haha, C. J., Smith, A. and Stahel, K. A., Tumor-associated membrane sialoglycoprotein on human small-cell lung carcinoma identified by the IgG2a monoclonal antibody SWA20. Cancer Res., 45, 4318–4323 (1988).
- Wawrzynczak, E. J., Derbyshire, E. J., Henry, R. V., Parnell, G. D., Smith, A., Waibel, R. and Stahel, R. A., Selective cytotoxic effect of a ricin A-chain immunotoxin nude with the monoclonal antibody SWA11 recognising a human small-cell-lung-cancer antigen. Brit. J. Cancer, 62, 410–414 (1990).
- Zangemeister-Wittke, U., Collinson, A. R., Fisch, I., Jones, R. M. L., Waibel, R., Lehman, H-P. and Stahel, R. A., Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer. Int. J. Cancer, 54, 1028–1035 (1993).
